Using newly developed assay, Tatebe and colleagues [27] in a recent small-scale study demonstrate significantly higher levels of phosphorylated p181 tau protein (P-tau) in the plasma in AD patients as compared to healthy controls, a finding confirmed also by other groups [28, 29]. The gene discussed is MAPT; the disease is Alzheimer disease.